Anti-CYTL1/ C17/ C4orf4 functional antibody

Anti-CYTL1/ C17/ C4orf4 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to CYTL1/CYTL1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0846-Ab-1/ GM-Tg-hg-SE0846-Ab-2Anti-Human CYTL1 monoclonal antibodyHuman
GM-Tg-rg-SE0846-Ab-1/ GM-Tg-rg-SE0846-Ab-2Anti-Rat CYTL1 monoclonal antibodyRat
GM-Tg-mg-SE0846-Ab-1/ GM-Tg-mg-SE0846-Ab-2Anti-Mouse CYTL1 monoclonal antibodyMouse
GM-Tg-cynog-SE0846-Ab-1/ GM-Tg-cynog-SE0846-Ab-2Anti-Cynomolgus/ Rhesus macaque CYTL1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0846-Ab-1/ GM-Tg-felg-SE0846-Ab-2Anti-Feline CYTL1 monoclonal antibodyFeline
GM-Tg-cang-SE0846-Ab-1/ GM-Tg-cang-SE0846-Ab-2Anti-Canine CYTL1 monoclonal antibodyCanine
GM-Tg-bovg-SE0846-Ab-1/ GM-Tg-bovg-SE0846-Ab-2Anti-Bovine CYTL1 monoclonal antibodyBovine
GM-Tg-equg-SE0846-Ab-1/ GM-Tg-equg-SE0846-Ab-2Anti-Equine CYTL1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0846-Ab-1/ GM-Tg-hg-SE0846-Ab-2; GM-Tg-rg-SE0846-Ab-1/ GM-Tg-rg-SE0846-Ab-2;
GM-Tg-mg-SE0846-Ab-1/ GM-Tg-mg-SE0846-Ab-2; GM-Tg-cynog-SE0846-Ab-1/ GM-Tg-cynog-SE0846-Ab-2;
GM-Tg-felg-SE0846-Ab-1/ GM-Tg-felg-SE0846-Ab-2; GM-Tg-cang-SE0846-Ab-1/ GM-Tg-cang-SE0846-Ab-2;
GM-Tg-bovg-SE0846-Ab-1/ GM-Tg-bovg-SE0846-Ab-2; GM-Tg-equg-SE0846-Ab-1/ GM-Tg-equg-SE0846-Ab-2
Products NameAnti-CYTL1 monoclonal antibody
Formatmab
Target NameCYTL1
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CYTL1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0846-Ag-1Recombinant multi-species CYTL1/ C17/ C4orf4 protein


    Target information

    Target IDGM-SE0846
    Target NameCYTL1
    Gene ID54360,231162,498392,711664,611137,101093015,505170,100069932
    Gene Symbol and Synonyms4930443F05Rik,4Cytl1,C17,C4orf4,Cyt1,CYTL1,Gm147,RGD1561846
    Uniprot AccessionQ9NRR1
    Uniprot Entry NameCYTL1_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000170891
    Target ClassificationN/A

    The target: CYTL1, gene name: CYTL1, also named as C17, C4orf4. C17 is a cytokine-like protein specifically expressed in bone marrow and cord blood mononuclear cells that bear the CD34 (MIM 142230) surface marker (Liu et al., 2000 [PubMed 10857752]).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.